Duyn A E, Kaspers G J, Pieters R, Van Zantwijk C H, Broekema G J, Hählen K, Veerman A J
Department of Pediatrics, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
Ann Hematol. 1999 Apr;78(4):163-71. doi: 10.1007/s002770050495.
Growth factors have been reported to enhance the cytotoxicity of anticancer agents. In our study we investigated the capacities of interleukin 3 (IL-3), interleukin 7 (IL-7), low-molecular-weight B-cell growth factor (lmw-BCGF), and IL-3 + 7 to induce proliferation and to modulate the drug resistance of childhood acute lymphoblastic leukemia (ALL) cells. Proliferation was assessed with the methyl-thiazole-tetrazolium (MTT) assay and other parameters. Cellular resistance to cytarabine, thioguanine, and prednisolone was measured using the MTT assay. In 19 samples containing >90% leukemic cells the proliferative response and the modulation of drug resistance was markedly heterogeneous between patient samples and between growth factors. All growth factors were able to stimulate proliferation significantly after 5 days of culture. lmw-BCGF was the most potent growth factor in this respect. Cytotoxicity of cytarabine and thioguanine was significantly increased by IL-7, that of thioguanine by IL-3 as well. IL-7 enhanced the cytotoxicity of thioguanine significantly more than IL-3 and lmw-BCGF and that of cytarabine more than IL-3. Cytotoxicity of prednisolone was not significantly influenced by any growth factor. In individual cases, growth factors reduced the cytotoxicity of the drugs. IL-3 + 7 did not add activity to the most potent single growth factor in both proliferation and drug resistance measurements. This study shows that IL-3, IL-7, and lmw-BCGF generally induce and occasionally inhibit proliferation of ALL cells. Furthermore, they may either increase or decrease cytotoxicity of anticancer drugs. This heterogeneous response to growth factors concerning induction of proliferation and modulation of drug resistance should be taken into account in their clinical use.
据报道,生长因子可增强抗癌药物的细胞毒性。在我们的研究中,我们调查了白细胞介素3(IL-3)、白细胞介素7(IL-7)、低分子量B细胞生长因子(lmw-BCGF)以及IL-3 + 7诱导儿童急性淋巴细胞白血病(ALL)细胞增殖和调节其耐药性的能力。通过甲基噻唑四氮唑(MTT)法和其他参数评估增殖情况。使用MTT法测量细胞对阿糖胞苷、硫鸟嘌呤和泼尼松龙的耐药性。在19个含有>90%白血病细胞的样本中,患者样本之间以及生长因子之间的增殖反应和耐药性调节存在明显异质性。培养5天后,所有生长因子均能显著刺激增殖。在这方面,lmw-BCGF是最有效的生长因子。IL-7可显著增加阿糖胞苷和硫鸟嘌呤的细胞毒性,IL-3也可增加硫鸟嘌呤的细胞毒性。IL-7增强硫鸟嘌呤细胞毒性的程度明显超过IL-3和lmw-BCGF,增强阿糖胞苷细胞毒性的程度超过IL-3。泼尼松龙的细胞毒性未受到任何生长因子的显著影响。在个别情况下,生长因子会降低药物的细胞毒性。在增殖和耐药性测量中,IL-3 + 7并未比最有效的单一生长因子增加活性。本研究表明,IL-3、IL-7和lmw-BCGF通常诱导ALL细胞增殖,偶尔也会抑制其增殖。此外,它们可能会增加或降低抗癌药物的细胞毒性。在临床应用中应考虑到生长因子在诱导增殖和调节耐药性方面的这种异质性反应。